Story perspectives

US Exempts Indian Medicines from Tariffs Amid Supply Risks

10/31/2025

38 7

Summary

Story summary

The United States has exempted Indian generic medicines from new tariffs, emphasizing cost control.
India relies heavily on China for active pharmaceutical ingredients, with imports rising from 62% to 87% between 2005 and 2024.
Germany also depends on China for antibiotic ingredients, importing 76% of its antibiotic ingredients from China.
Reports urge the United States, the European Union, and India to diversify sources to reduce supply-chain risk and support health diplomacy amid geopolitical disruptions.

1 of 1

Story summary

The United States has exempted Indian generic medicines from new tariffs, emphasizing cost control.
India relies heavily on China for active pharmaceutical ingredients, with imports rising from 62% to 87% between 2005 and 2024.
Germany also depends on China for antibiotic ingredients, importing 76% of its antibiotic ingredients from China.
Reports urge the United States, the European Union, and India to diversify sources to reduce supply-chain risk and support health diplomacy amid geopolitical disruptions.